Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: A systematic review

Transfusion

Volumn 54, Issue 4, 2014, Pages 1180-1191

  Vassallo, Ralph R ^a   Fung, Mark ^b   Rebulla, Paolo ^c   Duquesnoy, Rene ^d   Saw, Chee Loong ^e   Slichter, Sherrill J ^f   Tanael, Susano ^g   Shehata, Nadine ^g,h,i  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g CANADIAN BLOOD SERVICES   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BLEEDING; COCHRANE LIBRARY; EMBASE; HLA MATCHING; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; MEDLINE; MORTALITY; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

BLOOD GROUPING AND CROSSMATCHING; BLOOD PLATELETS; COHORT STUDIES; HISTOCOMPATIBILITY; HUMANS; PLATELET TRANSFUSION; PREDICTIVE VALUE OF TESTS; THROMBOCYTOPENIA;

EID: 84898875105     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12395     Document Type: Review

References (44)

1. Kerkhoffs JL, Eikenboom JC, van de Watering LM, van-Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A,. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008; 48: 1959-1965.
2. Slichter SJ, Davis K, Enright H, Braine H, Gernshimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114. (Pubitemid 40656162)
3. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge D,. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333-339. (Pubitemid 38029957)
4. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-1869.
5. Vassallo RR Jr,. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007; 14: 655-663. (Pubitemid 47494083)
6. Slichter SJ,. Platelet crossmatch testing for donor selection. Prog Clin Biol Res 1982; 88: 153-164.
7. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, Rowe JT, Saleh MN, Arndt P, Foley K, Masel D, Postoway N,. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32: 633-640.
8. Petz LD, Garratty G, Calhoun C, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM,. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-1456. (Pubitemid 32048531)
9. Pai SC, Lo SC, Tsai SJ, Chang JS, Lin DT, Lin KS, Lin I,. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50: 2318-2327.
10. Kakaiya RM, Gudino MD, Miller WV, Sherman LA, Katz AJ, Wakem CJ, Krugman DJ, Klatsky AU, Kiraly TR,. Four crossmatch methods to select platelet donors. Transfusion 1984; 24: 35-41. (Pubitemid 14180359)
11. Daly PA, Schiffer CA, Aisner J, Wiernik PH,. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243: 435-438. (Pubitemid 10207636)
12. Fowkes FG, Fulton PM,. Critical appraisal of published research: introductory guidelines. BMJ 1991; 302: 1136-1140.
13. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG,. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-12.
14. Sayed D, Bakry R, El-Sharkawy N, Zahran A, Khalaf MR,. Flow cytometric platelet cross-matching to predict platelet transfusion in acute leukemia. J Clin Apher 2011; 26: 23-28.
15. Ogden DM, Asfour A, Koller C, Lichtiger B,. Platelet crossmatches of single-donor platelet concentrates using a latex agglutination assay. Transfusion 1993; 33: 644-650. (Pubitemid 23237594)
16. O'Connell BA, Schiffer CA,. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990; 30: 314-317. (Pubitemid 20180824)
17. Freedman J, Gafni A, Garvey MB, Blanchette V,. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989; 29: 201-207. (Pubitemid 19141894)
18. Kickler TS, Ness PM, Braine HG,. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient. Am J Clin Pathol 1988; 90: 69-72.
19. Rachel JM, Summers TC, Sinor LT, Plapp FV,. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90: 63-68.
20. Wiita AP, Nambiar A,. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes. Transfusion 2012; 52: 2146-2154.
21. Levin MD, van der Holt B, de Veld JC, Gratama JW, de Vries W, van't Veer MB,. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients. Vox Sang 2004; 87: 291-298. (Pubitemid 39627158)
22. Gelb AB, Leavitt AD,. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997; 37: 624-630. (Pubitemid 27255832)
23. Köhler M, Dittmann J, Legler TJ, Lynen R, Humpe A, Riggert J, Neumeyer H, Pies A, Panzer S, Mayr WR,. Flow cytometric detection of platelet-reactive antibodies and application in platelet crossmatching. Transfusion 1996; 36: 250-255. (Pubitemid 26114468)
24. Sintnicolaas K, Löwenberg B,. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions. Br J Haematol 1996; 92: 1005-1010. (Pubitemid 26111172)
25. Gates K, MacPherson BR,. Retrospective evaluation of flow cytometry as a platelet crossmatching procedure. Cytometry 1994; 18: 123-128. (Pubitemid 24284336)
26. Chow MP, Yung CH, Hu HY, Tzeng JL, Lin JS, Lin WM, Lin CK,. HLA antibodies-the cause of platelet alloimmunization in Chinese. Am J Hematol 1992; 39: 15-19.
27. Heal JM, Blumberg N, Masel D,. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23-30. (Pubitemid 17111236)
28. Yam P, Petz LD, Scott EP, Santos S,. Platelet crossmatch tests using radiolabelled staphylococcal protein A or peroxidase anti-peroxidase in alloimmunized patients. Br J Haematol 1984; 57: 337-347. (Pubitemid 14106410)
29. Kickler TS, Braine HG, Ness PM, Koester A, Bias W,. A radiolabeled antiglobulin test for crossmatching platelet transfusions. Blood 1983; 61: 238-242. (Pubitemid 13137640)
30. Rebulla P, Morelati F, Revelli N, Villa MA, Paccapelo C, Nocco A, Greppi N, Marconi M, Cortelezzi A, Fracchiolla N, Martinelli G, Deliliers GL,. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004; 125: 83-89. (Pubitemid 38453283)
31. Freedman J, Garvey MB, Salomon de Friedberg Z, Hornstein A, Blanchette V,. Random donor platelet crossmatching: comparison of four platelet antibody detection methods. Am J Hematol 1988; 28: 1-7.
32. Freedman J, Hooi C, Garvey MB,. Prospective platelet crossmatching for selection of compatible random donors. Br J Haematol 1984; 56: 9-18. (Pubitemid 14211350)
33. Brand A, van Leeuwen A, Eernisse JG, van Rood JJ,. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978; 51: 781-788. (Pubitemid 8342547)
34. Chow MP, Yung CH, Hu HY, Tzeng JL, Lin WM, Lin CK,. Platelet crossmatching with lymphocytotoxicity test: an effective method in alloimmunized Chinese patients. Transfusion 1991; 31: 595-599.
35. McFarland JG, Aster RH,. Evaluation of four methods for platelet compatibility testing. Blood 1987; 69: 1425-1430. (Pubitemid 17088908)
36. Kickler TS, Braine H, Ness PM,. The predictive value of crossmatching platelet transfusion for alloimmunized patients. Transfusion 1985; 25: 385-389. (Pubitemid 15242047)
37. Ware R, Reisner EG, Rosse WF,. The use of radiolabeled and fluorescein-labeled antiglobulins in assays to predict transfusion outcome. Blood 1984; 63: 1245-1248. (Pubitemid 14100932)
38. Skogen B, Christiansen D, Husebekk A,. Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test. Transfusion 1995; 35: 832-836.
39. Lane D, Shivji S, Turner AR,. Solid phase platelet crossmatching versus complement dependent lymphocytotoxicity-clinical utility. Prog Clin Biol Res 1990; 337: 59-62.
40. Bowen TJ, Berman-Wong E, Dawson D, Herbut B, Smith L, Snider C, Hill L,. Comparison of three cross-match techniques to select platelet donors. Curr Stud Hematol Blood Transfus 1986; 52: 47-57.
41. Filip DJ, Duquesnoy RJ, Aster RH,. Predictive value of cross-matching for transfusion of platelet concentrates to alloimmunized patients. Am J Hematol 1976; 1: 471-479.
42. Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter S, Tanael S, Shehata N,. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013; 53: 2230-2242.
43. Slichter SJ, Bolgiano D, Kao KJ, Kickler TS, McFarland J, McCullough J, Woodson R,. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev 2011; 25: 102-110.
44. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH,. Relative importance of immune and nonimmune causes of platelet-refractoriness. Vox Sang 1994; 66: 200-205. (Pubitemid 24103656)